Acetamide, N-[4-[(2-pyridinylamino)sulfonyl]phenyl]- (BioDeep_00000171420)

   

human metabolite


代谢物信息卡片


N-{4-[(pyridin-2-yl)sulphamoyl]phenyl}ethanimidic acid

化学式: C13H13N3O3S (291.06775880000004)
中文名称:
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CC(=O)NC1=CC=C(C=C1)S(=O)(=O)NC2=CC=CC=N2
InChI: InChI=1S/C13H13N3O3S/c1-10(17)15-11-5-7-12(8-6-11)20(18,19)16-13-4-2-3-9-14-13/h2-9H,1H3,(H,14,16)(H,15,17)

描述信息

D000890 - Anti-Infective Agents > D013424 - Sulfanilamides

同义名列表

7 个代谢物同义名

N-{4-[(pyridin-2-yl)sulphamoyl]phenyl}ethanimidic acid; N-{4-[(pyridin-2-yl)sulfamoyl]phenyl}ethanimidic acid; Acetamide, N-[4-[(2-pyridinylamino)sulfonyl]phenyl]-; N-{4-[(pyridin-2-yl)sulphamoyl]phenyl}ethanimidate; N-{4-[(pyridin-2-yl)sulfamoyl]phenyl}ethanimidate; N-Acetylsulfapyridine; Acetylsulphapyridine



数据库引用编号

6 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Anne-Sophie De Koninck, Luitzen-Albert Groen, Heleen Maes, Alain Gaston Verstraete, Veronique Stove, Joris Richard Delanghe. An Unusual Type of Kidney Stone. Clinical laboratory. 2016; 62(1-2):235-9. doi: 10.7754/clin.lab.2015.150605. [PMID: 27012055]
  • Jing-Jing Ma, Cun-Gang Liu, Jin-Heng Li, Xiao-Mei Cao, Sheng-Li Sun, Xuan Yao. Effects of NAT2 polymorphism on SASP pharmacokinetics in Chinese population. Clinica chimica acta; international journal of clinical chemistry. 2009 Sep; 407(1-2):30-5. doi: 10.1016/j.cca.2009.06.025. [PMID: 19560446]
  • W M Awni, R A Braeckman, C S Locke, L M Dubé, G R Granneman. The influence of multiple oral doses of zileuton on the steady-state pharmacokinetics of sulfasalazine and its metabolites, sulfapyridine and N-acetylsulfapyridine. Clinical pharmacokinetics. 1995; 29 Suppl 2(?):98-104. doi: 10.2165/00003088-199500292-00014. [PMID: 8620678]
  • E Erturk, J B Casemento, K R Guertin, A S Kende. Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy. The Journal of urology. 1994 Jun; 151(6):1605-6. doi: 10.1016/s0022-5347(17)35314-4. [PMID: 7910643]
  • C J Buggé, S R Gautam, L E Parke, J T Mason, D B Garcia. Simultaneous determination of sulfasalazine and its metabolites sulfapyridine and N-acetylsulfapyridine in human serum by ion-pair high-performance liquid chromatography using a polymer-based column. Journal of pharmaceutical sciences. 1990 Dec; 79(12):1095-8. doi: 10.1002/jps.2600791211. [PMID: 1981912]
  • V S Chungi, L W Dittert, L Shargel. Pharmacokinetics of sulfasalazine metabolites in rats following concomitant oral administration of riboflavin. Pharmaceutical research. 1989 Dec; 6(12):1067-72. doi: 10.1023/a:1015938706685. [PMID: 2576130]
  • C Astbury, J S Dixon. Rapid method for the determination of either plasma sulphapyridine or sulphamethoxazole and their acetyl metabolites using high-performance liquid chromatography. Journal of chromatography. 1987 Feb; 414(1):223-7. doi: 10.1016/0378-4347(87)80045-2. [PMID: 3494739]
  • T Pullar, J A Hunter, H A Capell. Sulphasalazine in the treatment of rheumatoid arthritis: relationship of dose and serum levels to efficacy. British journal of rheumatology. 1985 Aug; 24(3):269-76. doi: 10.1093/rheumatology/24.3.269. [PMID: 2861876]
  • M E Sharp, S M Wallace, K W Hindmarsh, M A Brown. Acetylator phenotype and serum levels of sulfapyridine in patients with inflammatory bowel disease. European journal of clinical pharmacology. 1981; 21(3):243-50. doi: 10.1007/bf00627927. [PMID: 6119205]